drugset / Trial / NCT00921024

Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections

NCT00921024

Phase 2 Completed 129 enrolled Merck & Co., Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of intravenous CXA 101 and comparator in complicated urinary tract infection

Timeline

Start
2009-06-30
Primary completion
2010-02-25
Completion
2010-03-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ceftazidime Small molecule Intravenous
Subject Ceftolozane Small molecule Intravenous